Company / SG&A Expense
Krystal Biotech, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$146.7M
FY2025
5-year range
$40.4M / $146.7M
FY2021-FY2025
Trend
+29.1%
vs FY2024
Sector context
#94 of 213
Health Care
What the data says
At $147M, Krystal Biotech, Inc.'s sg&a expense ranks #120 of 213 in the Health Care sector. SG&A Expense has increased for 9 consecutive years, from $402,000 in FY2016 to $147M in FY2025.
Based on SEC 10-K filings.
$147M in FY2025 with a 5-year CAGR of +57.7%.
Increased from $98M to $147M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +23.6%
- 5-Year CAGR
- +57.7%
- 10-Year CAGR
- -
Sector benchmark
#120 of 213 in Health CareTop 56% of 213This company $146.7M Sector average $722.3M
▼
-79.7% below sector average
Key checks
Key Insights
- Krystal Biotech, Inc.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +57.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 29.1% year-over-year.
- Ranks #94 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $146.7M | +29.1% |
| FY2024 | $113.6M | +15.6% |
| FY2023 | $98.3M | +26.4% |
| FY2022 | $77.7M | +92.5% |
| FY2021 | $40.4M | +168.1% |
| FY2020 | $15.1M | +133.0% |
| FY2019 | $6.5M | +55.6% |
| FY2018 | $4.2M | +165.7% |
| FY2017 | $1.6M | +289.1% |
| FY2016 | $402.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026